On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock’s ...

Bayer upgraded to Buy at Goldman Sachs, saying risk/reward into H2 2025 looks positive and catalysts including upcoming litigation newsflow could support a re-rating over the medium term.

News about Goldman Sachs Group Inc., including commentary and archival articles published in The New York Times. Skip to content Skip to site index. ... By Benjamin Cunningham and Edu Bayer.

Investing.com -- Shares of Bayer AG (ETR: BAYGN) were up over 5% on Thursday after Goldman Sachs (NYSE: GS) upgraded the German pharmaceutical and life sciences company to a "buy" rating from "neutral ...

Goldman Sachs analyst James Quigley maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €30.00. The company’s shares closed yesterday at €25.94 ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of €30.00. The company’s shares closed last ...

Goldman Sachs raises its recommendation on Bayer to buy from neutral, and lifts its target price to 33 euros from 29.10 euros. Shares jump 4.9% to 26.55 euros. ([email protected]) ...

On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock’s ...

On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock’s ...

On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock’s ...